RxDoctor Payments Data

Thomas Tyree, MD

Internal Medicine · Saint Charles, MONPI 1841251048

Payments from drug & device makers

$1,328in general payments, 2019–2025

Across 14 payments — averaging $94.83 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$195
  • Sumitomo Pharma America, Inc.$126
  • Phathom Pharmaceuticals, Inc.$125
  • AstraZeneca$122
  • Johnson & Johnson$121
  • Otsuka America Pharmaceutical, Inc.$116
  • plus $523 from 6 others

What the payments were for

  • Food & beverage$1,327100%
  • Education$10%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,328 in reported general payments places this provider in the 75th percentile of 2,097 internal medicine providers in Missouri.

See all internal medicine providers in Missouri

Medicare billing

Part B allowed, 2024
$71,219
Medicare patients
304
Services billed
733

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban141$150,020
OzempicSemaglutide63$78,400
MounjaroTirzepatide24$42,007
XareltoRivaroxaban35$39,964
JardianceEmpagliflozin33$33,988
ArexvyRsvpref3 Antigen/As01e/Pf128$30,290
TrulicityDulaglutide16$27,791
LinzessLinaclotide31$27,742
RybelsusSemaglutide13$23,132
FarxigaDapagliflozin Propanediol20$22,360
MyrbetriqMirabegron11$14,332
Tresiba Flextouch U-100Insulin Degludec11$11,707
JanuviaSitagliptin Phosphate15$11,551
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr16$10,366
JanumetSitagliptin Phos/Metformin Hcl11$7,290

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$195$101,53176 claims
Johnson & JohnsonXarelto$121$39,96435 claims
AstraZenecaFarxiga, Symbicort$122$27,46331 claims
MerckJanuvia, Janumet$87$18,84126 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 2,097 internal medicine providers in Missouri.

Other internal medicine in Saint Charles

See the full list for Missouri

Where these figures come from

Is this you, or does something look wrong? →